Health Care

Medtronic announced a $42.9 billion deal to acquire rival medical device maker Covidien, creating a formidable competitor to Johnson & Johnson's device business.

Botox maker Allergan said its board rejected the latest buyout offer from Valeant Pharmaceuticals and Bill Ackman's Pershing Square.

The Center for Disease Control and Prevention reports someone loses a limb from diabetic complications every 20 seconds. But doctors at the University of Arizona Medical Center, in Tucson, Arizona, have found a way to prevent the development of these ulcers, and it's as simple as putting on a pair of socks

Three major drug companies announced positive results for melanoma on Monday, offering advances in the treatment of the deadliest type of skin cancer. 

Activist investor Bill Ackman is calling for a special meeting of Allergan shareholders in hopes of ousting six board members, according to a regulatory filing on Monday.

Valeant Pharmaceuticals said it would hike its cash-and-stock offer to buy Botox-maker Allergan -- a move that's backed by Pershing Square's Bill Ackman.

Valeant sweetened its takeover bid for Botox maker Allergan, offering to buy the company for $49.4 billion.

AstraZeneca shares slumped Tuesday after Pfizer said it would not make a formal bid to acquire its smaller British rival.

AstraZeneca rejected Pfizer’s final takeover offer on Monday, saying it still undervalues the drug giant. 

AstraZeneca is hoping to use its growing oncology pipeline, including a number of recent positive trial results, to fend off a takeover bid from rival Pfizer. 

Eli Lilly lost a patent case in the English High Court over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis.

AstraZeneca's chief executive said his company's board would consider a compelling offer from Pfizer, despite turning down previous offers from the firm.

Valeant plans to unveil an improved offer for Botox maker Allergan later this month, as the Canadian drug company seeks to rally shareholder support for a buyout.

Merck agreed to sell its consumer-care unit to German pharmaceutical giant Bayer for $14.2 billion, continuing a flurry of healthcare deals.

The pharmaceutical giant posted 1Q profits per share that beat the Street by two cents while revenue came in below expectations. Gloomy China Data Weigh on U.S. Stock Futures | Apple on Medical Tech Hiring Spree

CVS Caremark reported an 18% increase in its first-quarter earnings, as strength in the company's pharmacy services business lifted revenue.

AstraZeneca turned down a sweetened buyout offer of $106.4 billion from rival drug giant Pfizer, thwarting a move that would have created the world’s largest pharmaceutical company.

Botox-maker Allergan is reportedly hunting for a white knight after Valeant made a hostile buyout offer backed by Bill Ackman. 

Pfizer said Monday it made a nearly $100 billion bid to buy AstraZeneca earlier this year, and approached the firm earlier this month to resume talks. 

The medical-device maker said it would acquire orthopedic products company Biomet in a deal valued at about $13.35 billion.